Catherine, Princess of Wales makes first public appearance after dropping out of Royal Ascot
Kate visited the hospital garden in the southeast of England to 'celebrate the incredible healing power of nature,' according to Kensington Palace.
During the visit, the princess also met with patients and staff at the hospital's Cancer Wellbeing Centre 'to understand how gardens in healthcare settings play a crucial role in promoting good health outcomes, preventing poor health and supporting increased recovery time,' the palace said.
Kate, 43, has underlined the importance of nature in her health journey over the last year.
'Over the past year, nature has been my sanctuary,' she said in a video posted on X to mark Mental Health Awareness Week in May.
Kate revealed her cancer diagnosis and that she had started chemotherapy last March. As she underwent treatment, she stepped back from public life and only made a few rare appearances last summer. In September, she announced she had completed chemotherapy and was 'doing what I can to stay cancer free.'
Although she has taken on more appearances this year, the popular royal is understood to be working to find the right balance as she returns to public duties after treatment.
Before dropping out of Ascot at short notice, Kate had attended a number of engagements in recent weeks, including two major events in the royal calendar, the Trooping the Colour parade in London and the Order of the Garter service in Windsor.
She resumed in-person duties last week when she and Prince William invited Melinda French Gates for a meeting at Windsor Castle. They were understood to have discussed their philanthropic work, according to Britain's PA Media news agency.
Kate's visit to Colchester Hospital on Wednesday coincided with the hospital accepting a donation of 50 'Catherine's Rose' plants, a specially-bred rose named in her honor by the Royal Horticultural Society. She planted some of these roses, which, when sold commercially, will have their proceeds donated to The Royal Marsden Cancer Charity.
Kate has become deeply involved in the charity since her diagnosis. In January, Kensington Palace announced that she had been named the joint patron of The Royal Marsden NHS Foundation Trust, the specialist cancer center in Chelsea, west London, where she was treated.
Funds from the sale of these roses will be used to help the charity establish a specialist program helping cancer patients live well with the disease, and after their treatment has been completed.
CNN's Lauren Said-Moorhouse contributed reporting.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Product recall round up: Popular Coles $6.50 pantry staple, and baby products for choking risk
This week, several products were recalled from shops Coles, with a popular pantry staple and items made for babies and young children being taken off shelves. Unfortunately, in some cases, incidents have occurred prior to the recall. People who have purchased these items will be entitled to a refund or a method to fix the issue. Aussies should check their homes for the following items: RELATED: Woolworths customer left shocked by $52 mistake: 'Triple check' $2 Woolworths item solves problem with most hated cooking task: 'Life changing' Kmart shopper's $9 solution to annoying winter issue: 'Didn't know it existed' Coles supermarkets have issued a product recall on their name-brand peanut butter, available in both smooth and crunchy varieties, in 1kg jars. Customers who have purchased Coles 1kg Smooth Peanut Butter and/or Coles 1kg Crunchy Peanut Butter are advised not to consume the product and instead return it to the store where they made the purchase. The reason behind the recall is potential aflatoxin contamination. Food products containing aflatoxin may cause illness or injury if consumed. Aflatoxins are toxic compounds produced by certain moulds that can grow on food crops in warm, humid environments. Health risks associated with consuming contaminated products include liver damage and immune system suppression. Any consumers concerned about their health should consult a medical professional. The two varieties of Coles peanut butter, which have been available for sale in Coles Supermarkets and online nationally, sell for $6.50. If you purchased the peanut butter online instead of in-store, you can receive a refund or credit by contacting Coles Online Customer Care on 1800 455 400. EZOneDeal has issued a recall on their Infant Feeding Pillow in colours pink and cyan with the product codes Z3007 and Z3008. The ACCC states, "Baby bottle self-feeding devices pose a possible risk to babies from choking, aspiration pneumonia, suffocation and ear infections. "These products are subject to a safety warning notice." They add, "There have been reports of infant fatalities associated with the use of baby bottle self-feeding devices." Consumers who have purchased this product should stop using it immediately and dispose of it safely to prevent it from being used by someone else. Contact on contactus@ or call (03) 7065 6422 between 10am and 3pm Monday to Friday for a refund or store credit, or if you have sold or gifted it to another person. EZOneDeal has also issued a recall on their Baby Kids Head Support in the colours blue and red, with the product codes. "Car seat head straps can increase the risk of spinal cord injury or death by altering head and neck alignment during a crash," the ACCC writes. "They may also pose a suffocation or strangulation risk if they slip around the child's mouth or neck. "These products are the subject of a safety warning notice." SHOP: 🦥 Boody's new range in sizes S to XL are 'the softest sets you'll ever wear': 'Comfy and chic' 🧹 Up to $600 off Roborock gadgets in massive EOFY sale: 'Worth the money' 😃 Aussie's multi-million dollar business idea after job rejection: 'Suddenly went viral' They add that, unfortunately, incidents and injuries have occurred with this product. If you have purchased this product, stop using it and dispose of it immediately to prevent it from being used by anyone else. Contact on contactus@ or call (03) 7065 6422 between 10am and 3pm Monday to Friday for a refund or store credit, or if you have sold or gifted it to another person.
Yahoo
2 hours ago
- Yahoo
Enrolment concludes in Belite Bio's trial of Tinlarebant for geographic atrophy
Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant in individuals with geographic atrophy (GA) in dry age-related macular degeneration (AMD). This multicentre, randomised, placebo-controlled, double-masked, global trial is crucial in evaluating the therapy's potential to minimise the atrophic lesion growth rate in these patients. It has enrolled 500 participants across various sites in the US, the UK, the Czech Republic, France, Switzerland, Taiwan, Australia, and China. Tinlarebant, a one-daily tablet, is being developed as an early intervention to preserve retinal tissue health and integrity in those with Stargardt disease type 1 (STGD1) and GA. At present, there are no treatments approved by the Food and Drug Administration (FDA) for STGD1 and no approved oral treatments for GA. The tablet has received fast track, rare paediatric disease, and breakthrough therapy designations in the US, orphan drug status in the US, Japan, and Europe, and Sakigake designation in Japan for STGD1. Tinlarebant is also being evaluated in a Phase III trial (DRAGON) and a Phase II/III trial (DRAGON II) for adolescent STGD1 individuals, in addition to the PHOENIX trial for GA subjects. Belite Bio CEO and chairman Dr Tom Lin said: 'Completing enrolment in the PHOENIX trial marks an important milestone for Belite Bio as we advance our lead candidate, Tinlarebant, for the treatment of geographic atrophy. 'This achievement brings us one step closer to evaluating the potential of Tinlarebant to slow atrophic lesion growth in this serious and progressive disease for which there are no approved oral treatments. There remains a significant unmet need for this patient population.' The company develops new treatments for degenerative retinal diseases like STGD1 and GA. Last year, the company submitted an application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a trial of Tinlarebant for adolescent STGD1 treatment. "Enrolment concludes in Belite Bio's trial of Tinlarebant for geographic atrophy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Ministers face backbench calls to widen access to top tier of sickness benefits
Ministers are facing Labour backbench calls to widen access to their proposed top tier of sickness benefits. Labour backbencher Graeme Downie has proposed a welfare reform Bill amendment, so universal credit claimants with Parkinson's or multiple sclerosis who cannot work do not face repeated medical assessments to receive a payout. If MPs back his amendment, patients with 'evolving' needs who cannot work could also qualify for a higher rate of benefits. The Government's Bill has already cleared its first Commons hurdle at second reading, after work and pensions minister Sir Stephen Timms vowed not to restrict eligibility for the personal independence payment (Pip), with any changes coming in only after a review of the benefit. To meet his promise, ministers have had to table amendments to their own draft new law, to remove one of its seven clauses, which MPs will debate next Wednesday. Universal credit claimants with Parkinson's 'are already possibly struggling financially', Mr Downie told the PA news agency ahead of the debate. He added: 'The cost of living with a condition like Parkinson's can be very high. 'You may well require or need additional support.' The Dunfermline and Dollar MP said patients who struggle with their motor control might buy pre-chopped vegetables or chicken. 'Those things are expensive, so if you're already on universal credit and you're struggling, being able to do that significantly impacts your health, it significantly impacts your ability to live properly,' he continued. As part of the Government's reforms, the Department for Work and Pensions has proposed a new 'severe conditions criteria' for universal credit. Claimants in this category will be entitled to a higher rate of the benefit, and will not be routinely reassessed to receive money. To qualify, claimants must have limited capability for work or work-related activity (LCWRA) and symptoms which 'constantly' apply. Mr Downie's amendment would expand these criteria to claimants with 'a fluctuating condition'. It would cover 'conditions like Parkinson's but also multiple sclerosis, ME (myalgic encephalomyelitis), long Covid and a whole range of other conditions where, you know, in the morning things could be really good and in the afternoon things could be really bad, and even hour by hour things could change', he said. 'I felt it was necessary to table an amendment to really probe what the Government's position is on this, and ensuring that people with Parkinson's and conditions like that are not excluded from even applying and being considered.' Mr Downie's proposal has backing from 23 cross-party MPs. Juliet Tizzard, external relations director at Parkinson's UK, said: 'Criteria in the Bill say that a new claimant for the universal credit health payment will have to be 'constantly' unable to perform certain activities to qualify. 'This doesn't work for people with Parkinson's, whose symptoms change throughout the day. 'People with Parkinson's and other fluctuating conditions like multiple sclerosis will be effectively excluded from getting all the financial support they need. 'The Government has responded to our call and withdrawn the damaging restrictions to Pip. 'Now, they must do the same with the universal credit health element. The health of many people with Parkinson's is in their hands.'
